EMA News
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Get critical EMA regulatory updates for drug approvals, clinical trials, and market access in Europe & UK. Stay ahead of pharma compliance.
Showing 1–12 of 16 articles
Quick answer
NovaPharmaNews EMA News hub for FDA covers 16 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Global hematology trials keep research patient-centered and regionally relevant
Prescription Drug Freight Fraud June 2026 report: what the record shows
EMA backs datopotamab deruxtecan, but lung cancer access remains unclear
EMA backs datopotamab deruxtecan for advanced lung cancer
Eli Lilly raises 2026 revenue guidance on Mounjaro demand
Roche reports positive Phase 3 results for trontinemab in Alzheimer's disease
Novo Nordisk CagriSema Phase 3 Results: Obesity Catalyst Update
Novo Nordisk CagriSema Phase 3 Obesity Results Signal Key Catalyst
Top 10 Pharmaceutical Stocks to Buy for June 2026: A B2B Analysis
HaloMD Lawsuit Update: Highmark Health Alleges 'Sham Letter' and Misleading Data in No Surprises Act Dispute
Navigating Demands for Unvaccinated Donor Blood: A Hospital's Ethical and Operational Challenge
The Demand for Unvaccinated Blood Transfusions: A Growing Concern
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.